💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Ajanta Pharma Limited is an India-based specialty pharmaceutical company. It provides a comprehensive range of specialty branded generic products targeting a broad range of chronic and acute therapies. It is focused on branded generic businesses across India, Asia, and…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A high-quality, fast-growing business, fairly priced.
Ajanta Pharma is scored on the pharma / healthcare framework. It keeps a healthy 18.8% of every rupee of sales as net profit. Cash conversion lags the reported profit (CFO/PAT 0.50×) — worth a closer look. Free cash flow is worth about 0.2% of its market value.
Over the last 3 years revenue compounded at 14%/yr and profit at 22%/yr. Book value has grown 10%/yr. Return on equity is an elite 26.0%. In the latest quarter profit grew 16% versus the prior quarter.
At 39× earnings, the stock sits at the 57th percentile of its own 3.6-year range — the middle of where it has historically traded. Today's price implies ~16%/yr earnings growth for a decade. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 32.73 | — | — |
| P/B | 8.51 | 4.11 | worse |
| EV/EBITDA | 21.83 | 19.15 | worse |
| ROE | 25.99 | — | — |
| ROCE | 33.9 | 6.87 | better |
| ROA | 19.65 | — | — |
| Quick Ratio | 1.98 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Revenue has grown every year across all 4 financial years shown. 14% CAGR over 3 years — steady double-digit compounder. Growth is accelerating — latest year outpaced the prior year's rate.
Net profit has risen every year — the hallmark of a compounder. Profit is growing faster than revenue (22% vs 14%) — margin expansion is at work.
Operating margin has expanded from 19% to 24% — the business is keeping more of each rupee earned.
ROE at 23% — the business earns well above its cost of equity. Capital efficiency improving — ROE up 6pp across the window.
EPS has grown every year — each share earns more than the last, consistently. 23% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Financing outflows in consecutive years — balance-sheet discipline through debt repayment or dividends.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue rose 8% sequentially — momentum is building. Run-rate stepping up — recent quarters average 22% above earlier ones.
Profit jumped 16% QoQ — check if this is operating leverage or a one-off item.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoter holding at 63.5% — majority control intact. Promoters reduced 2.8pp over 4 quarters — watch whether this is planned divestment or pledge invocations. MF holding up 2.5pp — domestic institutional discovery underway.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.